{
  "issued_date": "2010-10-04", 
  "original_url": "http://www.mhra.gov.uk/Publications/Safetywarnings/MedicalDeviceAlerts/CON096755", 
  "doc_details": {
    "Type": "Medical Device Alert", 
    "Series No": "MDA/2010/078", 
    "Audience": "Healthcare professionals", 
    "Published": "4 October 2010 at 16:45", 
    "Format": "Electronic and paper", 
    "Size": "A4", 
    "Pages": "4", 
    "Price": "Free", 
    "ISBN/ISSN": "None", 
    "Author": "", 
    "Copyright": "Crown"
  }, 
  "_assets": [], 
  "body": "## Device\n\nSilicone gel filled breast implants manufactured by Poly Implant Prothese (PIP).\n\nAll devices implanted after 1 January 2001.\n\n## Problem\n\nClinical management of women implanted with PIP silicone gel filled implants.\n\nOn Tuesday 30 March 2010, the [French medical device regulatory authority (AFSSAPS)](http://www.afssaps.fr/) informed the MHRA that it had suspended the marketing, distribution, export and the use of silicone gel filled breast implants manufactured by PIP (a French breast implant manufacturer). AFSSAPS recalled all of these devices. The MHRA issued [MDA/2010/025](http://www.mhra.gov.uk/home/ssLINK/CON076499) on 31 March 2010 advising UK clinicians not to implant these devices.\n\nAFSSAPS had carried out an inspection of the PIP manufacturing plant and established that breast implants manufactured by the company since 2001 had been filled with a silicone gel with a composition different from that approved.\n\nAFSSAPS has carried out testing of affected implants to look at the genotoxicity (potential for cancer), chemical toxicity of the filler material and mechanical properties of the implant shell. The MHRA also commissioned tests to look at genotoxicity and chemical toxicity.\n\nTest results have not shown any evidence of genotoxicity or chemical toxicity of the filler material. One of the French genotoxicity tests was, however, inconclusive and further testing will be conducted by AFSSAPS with results expected in early 2011.\n\nMechanical testing of the implant shells carried out by AFSSAPS suggests that there may be an increased risk of rupture. However, the Therapeutic Goods Administration (TGA) of the Australian government also carried out tests on PIP silicone gel filled breast implants and found that these implants conformed to the relevant international standards for this type of product, including those for gel cytotoxicity and shell strength.\n\n## Action\n\nImplanting surgeons/implanting centres:  \n  \n  * Identify women who were implanted with PIP silicone gel filled implants after 1 January 2001.  \n  * Reassure them that there is no current evidence of health risk associated with the filler and there is no indication for routine action in the form of explantation or ultrasound.  \n  * Advise them that further information about the testing (see problem) is available on the MHRA website and that further information about clinical management is available on the websites of the [British Association of Plastic, Reconstructive and\u00a0Aesthetic Surgeons (BAPRAS)](http://www.bapras.org.uk/)\u00a0(external link) and the [Association of Breast Surgery (ABS) (external link).(external link).](http://www.associationofbreastsurgery.org.uk/Content/home.aspx)  \n  \nGPs:  \n  \n  * Advise women who are concerned about their PIP implants to consult their implanting surgeon or implanting centre.  \n  \nNote: the recommendations in this MDA update the advice given in [MDA/2010/025](http://www.mhra.gov.uk/home/ssLINK/CON076499).\n\n## Distribution\n\nThis MDA has been distributed to:  \n  \n  * NHS trusts in England (chief executives)  \n  * HSC trusts in Northern Ireland (chief executives)  \n  * NHS boards in Scotland (chief executives)  \n  * NHS boards and trusts in Wales (chief executives)  \n  * Primary care trusts in England (chief executives)  \n  \n  \nOnward distribution  \nPlease bring this notice to the attention of all who need to know or be aware of it. This may include distribution by:\n\nTrusts to:  \nCAS and SABS (NI) liaison officers for onward distribution to all relevant staff including:  \n  \n  * Directors of surgical units involved in breast construction  \n  * Medical directors  \n  * Nurse executive directors  \n  * Plastic surgeons and all surgeons involved in breast reconstruction or augmentation \u2022 Specialist nurses involved in breast cancer care  \n  \nPrimary care trusts to:  \nCAS liaison officers for onward distribution to all relevant staff including:  \n  \n  * General practitioners  \n  * Practice managers  \n  * Practice nurses  \n  \nEstablishments registered with the Care Quality Commission (CQC) (England only) to:  \nThe MHRA considers this information to be important to:  \n  \n  * Breast augmentation centres  \n  * Hospitals in the independent sector  \n  * Independent treatment centres  \n  * Private medical practitioners  \n  \n## Feedback\n\nIf you have any comments or feedback on this Medical Device Alert, please email us at: [dts@mhra.gsi.gov.uk](mailto:dts@mhra.gsi.gov.uk) \u00a0\n\n## England\n\nIf you are in England, please send enquiries about this notice to the MHRA, quoting reference number MDA/2010/078 or 2010/003/030/081/019.\n\nPlease note that telephone numbers for the MHRA contacts below will change on 25 October 2010. From that date please contact the MHRA Central Enquiry Point on 020 3080 6000 and ask for the person by name.\n\nTechnical aspects  \nBayode Adisa or Ian Smith  \n  \nTel: 020 7084 3223/3306  \nEmail: [bayode.adisa@mhra.gsi.gov.uk](mailto:bayode.adisa@mhra.gsi.gov.uk) or\u00a0[ian.smith@mhra.gsi.gov.uk](mailto:ian.smith@mhra.gsi.gov.uk)\n\nClinical aspects  \nDr Susanne Ludgate\n\nTel: 020 7084 3123  \nEmail: [susanne.ludgate@mhra.gsi.gov.uk](mailto:susanne.ludgate@mhra.gsi.gov.uk)\n\nHow to report adverse incidents  \nPlease report via our website: [Reporting adverse incidents involving medical devices](http://www.mhra.gov.uk/Safetyinformation/Reportingsafetyproblems/Devices/index.htm).  \nFurther information about CAS can be found on the [Central Alerting System website](https://www.cas.dh.gov.uk/Home.aspx) (external link)\n\n## Northern Ireland\n\nAlerts in Northern Ireland will continue to be distributed via the NI SABS system. \n\nEnquiries and adverse incident reports in Northern Ireland should be addressed to:  \n  \nNorthern Ireland Adverse Incident Centre  \nHealth Estates Investment Group  \nRoom 17  \nAnnex 6  \nCastle Buildings  \nStormont Estate  \nDundonald  \nBT4 3SQ\n\nTel: 02890 523 704  \nFax: 02890 523 900\n\nEmail: [NIAIC@dhsspsni.gov.uk](mailto:NIAIC@dhsspsni.gov.uk)\n\n[Northern Ireland Adverse Incident Centre (NIAIC)](http://www.dhsspsni.gov.uk/index/hea/niaic.htm) (external link)\n\nHow to report adverse incidents in Northern Ireland  \nPlease report directly to NIAIC, further information can be found on the [NIAIC website](http://www.dhsspsni.gov.uk/niaic) (external link).  \nFurther information about SABS can be found on the [SABS website](http://sabs.dhsspsni.gov.uk/NISABS/default.aspx?CATID=3) (external link).\n\n## Scotland\n\nEnquiries and adverse incident reports in Scotland should be addressed to:\n\nIncident Reporting and Investigation Centre  \nHealth Facilities Scotland  \nNHS National Services Scotland  \nGyle Square  \n1 South Gyle Crescent  \nEdinburgh  \nEH12 9EB\n\nTel: 0131 275 7575  \nFax: 0131 314 0722\n\nEmail: [nss.iric@nhs.net](mailto:nss.iric@nhs.net)\n\n[Health Facilities Scotland - Incident Reporting and Investigation Centre](http://www.hfs.scot.nhs.uk/online-services/incident-reporting-and-investigation-centre-iric/) (external link).\n\n## Wales\n\nEnquiries in Wales should be addressed to:\n\nDr Sara Hayes  \nSenior Medical Officer  \nMedical Device Alerts  \nWelsh Assembly Government  \nCathays Park  \nCardiff  \nCF10 3NQ\n\nTel: 029 2082 3922\n\nEmail: [Haz-Aic@wales.gsi.gov.uk](mailto:Haz-Aic@wales.gsi.gov.uk)\n", 
  "raw_html": "<div id=\"inner_tab_content\">\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\t\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\t\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\t\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\t\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t<h2 class=\"sw\">Device</h2><div class=\"content_section active_content_section\" id=\"Device\">\r\n\t\t\t\t\t\t\t\t<p><font class=\"h4\">Silicone gel filled breast implants manufactured by Poly Implant Prothese (PIP).</font></p><p><font class=\"h4\">All devices implanted after 1 January 2001.</font></p>\r\n\t\t\t\t\t\t\t</div>\r\n<h2 class=\"sw\">Problem</h2><div class=\"content_section\" id=\"Problem\">\r\n\t\t\t\t\t\t\t\t<p><font class=\"h4\">Clinical management of women implanted with PIP silicone gel filled implants.</font></p><p>On Tuesday 30 March 2010, the <a href=\"http://www.afssaps.fr/\" target=\"_blank\">French medical device regulatory authority (AFSSAPS)</a> informed the MHRA that it had suspended the marketing, distribution, export and the use of silicone gel filled breast implants manufactured by PIP (a French breast implant manufacturer). AFSSAPS recalled all of these devices. The MHRA issued <a href=\"http://www.mhra.gov.uk/home/ssLINK/CON076499\">MDA/2010/025</a> on 31 March 2010 advising UK clinicians not to implant these devices.</p><p>AFSSAPS had carried out an inspection of the PIP manufacturing plant and established that breast implants manufactured by the company since 2001 had been filled with a silicone gel with a composition different from that approved.</p><p>AFSSAPS has carried out testing of affected implants to look at the genotoxicity (potential for cancer), chemical toxicity of the filler material and mechanical properties of the implant shell. The MHRA also commissioned tests to look at genotoxicity and chemical toxicity.</p><p>Test results have not shown any evidence of genotoxicity or chemical toxicity of the filler material. One of the French genotoxicity tests was, however, inconclusive and further testing will be conducted by AFSSAPS with results expected in early 2011.</p><p>Mechanical testing of the implant shells carried out by AFSSAPS suggests that there may be an increased risk of rupture. However, the Therapeutic Goods Administration (TGA) of the Australian government also carried out tests on PIP silicone gel filled breast implants and found that these implants conformed to the relevant international standards for this type of product, including those for gel cytotoxicity and shell strength.</p>\r\n\t\t\t\t\t\t\t</div>\r\n<h2 class=\"sw\">Action</h2><div class=\"content_section\" id=\"Action\">\r\n\t\t\t\t\t\t\t\t<p>Implanting surgeons/implanting centres:</p><ul>\r\n\t\t\t\t<li>Identify women who were implanted with PIP silicone gel filled implants after 1 January 2001.</li>\r\n\t\t\t\t<li>Reassure them that there is no current evidence of health risk associated with the filler and there is no indication for routine action in the form of explantation or ultrasound.</li>\r\n\t\t\t\t<li>Advise them that further information about the testing (see problem) is available on the MHRA website and that further information about clinical management is available on the websites of the <a href=\"http://www.bapras.org.uk/\" target=\"_blank\">British Association of Plastic, Reconstructive and&#160;Aesthetic Surgeons (BAPRAS)</a>&#160;(external link) and the <a href=\"http://www.associationofbreastsurgery.org.uk/Content/home.aspx\" target=\"_blank\">Association of Breast Surgery (ABS) (external link).<font color=\"#555555\">(external link)</font>.</a></li></ul><p>GPs:</p><ul>\r\n\t\t\t\t<li>Advise women who are concerned about their PIP implants to consult their implanting surgeon or implanting centre.</li></ul><p>Note: the recommendations in this MDA update the advice given in <a href=\"http://www.mhra.gov.uk/home/ssLINK/CON076499\">MDA/2010/025</a>.</p>\r\n\t\t\t\t\t\t\t</div>\r\n<h2 class=\"sw\">Distribution</h2><div class=\"content_section\" id=\"Distribution\">\r\n\t\t\t\t\t\t\t\t<p>This MDA has been distributed to:</p><ul>\r\n\t\t\t\t<li>NHS trusts in England (chief executives)</li>\r\n\t\t\t\t<li>HSC trusts in Northern Ireland (chief executives)</li>\r\n\t\t\t\t<li>NHS boards in Scotland (chief executives)</li>\r\n\t\t\t\t<li>NHS boards and trusts in Wales (chief executives)</li>\r\n\t\t\t\t<li>Primary care trusts in England (chief executives)</li></ul><p><br><font class=\"h3\">Onward distribution</font><br>Please bring this notice to the attention of all who need to know or be aware of it. This may include distribution by:</p><p><span>Trusts to:</span><br>CAS and SABS (NI) liaison officers for onward distribution to all relevant staff including:</p><ul>\r\n\t\t\t\t<li>Directors of surgical units involved in breast construction</li>\r\n\t\t\t\t<li>Medical directors</li>\r\n\t\t\t\t<li>Nurse executive directors</li>\r\n\t\t\t\t<li>Plastic surgeons and all surgeons involved in breast reconstruction or augmentation &#8226; Specialist nurses involved in breast cancer care</li></ul><p><span>Primary care trusts to:</span><br>CAS liaison officers for onward distribution to all relevant staff including:</p><ul>\r\n\t\t\t\t<li>General practitioners</li>\r\n\t\t\t\t<li>Practice managers</li>\r\n\t\t\t\t<li>Practice nurses</li></ul><p><span>Establishments registered with the Care Quality Commission (CQC) (England only) to:</span><br>The MHRA considers this information to be important to:</p><ul>\r\n\t\t\t\t<li>Breast augmentation centres</li>\r\n\t\t\t\t<li>Hospitals in the independent sector</li>\r\n\t\t\t\t<li>Independent treatment centres</li>\r\n\t\t\t\t<li>Private medical practitioners</li></ul>\r\n\t\t\t\t\t\t\t</div>\r\n<h2 class=\"sw\">Feedback</h2><div class=\"content_section\" id=\"Feedback\">\r\n\t\t\t\t\t\t\t\tIf you have any comments or feedback on this Medical Device Alert, please email us at: <a href=\"mailto:dts@mhra.gsi.gov.uk\">dts@mhra.gsi.gov.uk</a> &#160;\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t<h2 class=\"sw\">England</h2><div class=\"content_section\" id=\"England\">\r\n\t\t\t\t\t\t\t\t\t<p>If you are in England, please send enquiries about this notice to the MHRA, quoting reference number <span>MDA/2010/078</span> or <span>2010/003/030/081/019.</span></p><p><span>Please note that telephone numbers for the MHRA contacts below will change on 25 October 2010. From that date please contact the MHRA Central Enquiry Point on 020 3080 6000 and ask for the person by name.</span></p><p><span>Technical aspects</span><br>Bayode Adisa or Ian Smith<br><br>Tel: 020 7084 3223/3306<br>Email: <a href=\"mailto:bayode.adisa@mhra.gsi.gov.uk\">bayode.adisa@mhra.gsi.gov.uk</a> or&#160;<a href=\"mailto:ian.smith@mhra.gsi.gov.uk\">ian.smith@mhra.gsi.gov.uk</a></p><p><span>Clinical aspects</span><br>Dr Susanne Ludgate</p><p>Tel: 020 7084 3123<br>Email: <a href=\"mailto:susanne.ludgate@mhra.gsi.gov.uk\">susanne.ludgate@mhra.gsi.gov.uk</a></p><p><font class=\"h3\">How to report adverse incidents</font><br>Please report via our website: <a href=\"http://www.mhra.gov.uk/Safetyinformation/Reportingsafetyproblems/Devices/index.htm\">Reporting adverse incidents involving medical devices</a>.<br>Further information about CAS can be found on the <a href=\"https://www.cas.dh.gov.uk/Home.aspx\" target=\"_blank\">Central Alerting System website</a> (external link)</p>\r\n\t\t\t\t\t\t\t\t</div>\r\n<h2 class=\"sw\">Northern Ireland</h2><div class=\"content_section\" id=\"Northern Ireland\">\r\n\t\t\t\t\t\t\t\t\tAlerts in Northern Ireland will continue to be distributed via the NI SABS system. <p>Enquiries and adverse incident reports in Northern Ireland should be addressed to:<br><br>Northern Ireland Adverse Incident Centre<br>Health Estates Investment Group<br>Room 17<br>Annex 6<br>Castle Buildings<br>Stormont Estate<br>Dundonald<br>BT4 3SQ</p><p>Tel: 02890 523 704<br>Fax: 02890 523 900</p><p>Email: <a href=\"mailto:NIAIC@dhsspsni.gov.uk\">NIAIC@dhsspsni.gov.uk</a></p><p><a href=\"http://www.dhsspsni.gov.uk/index/hea/niaic.htm\" target=\"_blank\">Northern Ireland Adverse Incident Centre (NIAIC)</a> (external link)</p><p><font class=\"h3\">How to report adverse incidents in Northern Ireland</font><br>Please report directly to NIAIC, further information can be found on the <a href=\"http://www.dhsspsni.gov.uk/niaic\" target=\"_blank\">NIAIC website</a> (external link).<br>Further information about SABS can be found on the <a href=\"http://sabs.dhsspsni.gov.uk/NISABS/default.aspx?CATID=3\" target=\"_blank\">SABS website</a> (external link).</p>\r\n\t\t\t\t\t\t\t\t</div>\r\n<h2 class=\"sw\">Scotland</h2><div class=\"content_section\" id=\"Scotland\">\r\n\t\t\t\t\t\t\t\t\t<p>Enquiries and adverse incident reports in Scotland should be addressed to:</p><p>Incident Reporting and Investigation Centre<br>Health Facilities Scotland<br>NHS National Services Scotland<br>Gyle Square<br>1 South Gyle Crescent<br>Edinburgh<br>EH12 9EB</p><p>Tel: 0131 275 7575<br>Fax: 0131 314 0722</p><p>Email: <a href=\"mailto:nss.iric@nhs.net\">nss.iric@nhs.net</a></p><p><a href=\"http://www.hfs.scot.nhs.uk/online-services/incident-reporting-and-investigation-centre-iric/\" target=\"_blank\">Health Facilities Scotland - Incident Reporting and Investigation Centre</a> (external link).</p>\r\n\t\t\t\t\t\t\t\t</div>\r\n<h2 class=\"sw\">Wales</h2><div class=\"content_section\" id=\"Wales\">\r\n\t\t\t\t\t\t\t\t\t<p>Enquiries in Wales should be addressed to:</p><p>Dr Sara Hayes<br>Senior Medical Officer<br>Medical Device Alerts<br>Welsh Assembly Government<br>Cathays Park<br>Cardiff<br>CF10 3NQ</p><p>Tel: 029 2082 3922</p><p>Email: <a href=\"mailto:Haz-Aic@wales.gsi.gov.uk\">Haz-Aic@wales.gsi.gov.uk</a></p>\r\n\t\t\t\t\t\t\t\t</div>\r\n</div>\r\n\t\t\t", 
  "title": "Medical Device Alert: Silicone gel filled breast implants manufactured by PIP (Poly Implant Prothese) (MDA/2010/078)", 
  "alert_type": [
    "devices"
  ], 
  "medical_specialism": [
    "general-practice"
  ]
}